Drug Information: A Guide for Pharmacists, Fourth Edition

by Malone, Patrick; Kier, Karen; Stanovich, John

• ISBN13: 9780071624954
• ISBN10: 0071624953
• Edition: 4th
• Format: Paperback
• Copyright: 2011-08-01
• Publisher: McGraw-Hill Medical

Summary

Everything pharmacists need to know about managing drug information for better patient outcomesDrug Information: A Guide for Pharmacists, 4eteaches pharmacists how to more effectively and efficiently research, interpret, collate and disseminate drug information in the most usable form possible.The book discusses how to determine what information is needed and how to respond adequately to requests for information. It also covers the ethical and legal aspects of drug information management.Features NEWcoverage of patient safety, project design and organizational problem solving NEWkey points added to each chapter NEWcase studies added to add real world relevance NEWstudy questions integrated throughout the chapters

Table of Contents

Chapter One. Introduction to the Concept of Medication Information
Mary Lea Gora-Harper and J. Russell May
Chapter Two. Formulating Effective Responses and Recommendations: A Structured Approach
Karim Anton Calis and Amy Heck Sheehan
Chapter Three. Drug Information Resources
Kelly M. Shields and Elaine Blythe
Chapter Four. Literature Evaluation I: Controlled Clinical Trial Evaluation
Michael Kendrach, Maisha Kelly Freeman, Terri M. Wensel, and Peter J. Hughes
Chapter Five. Literature Evaluation II: Beyond the Basics
Patrick J. Bryant, Karen P. Norris, Cydney E. McQueen, and Elizabeth A. Poole
Chapter Six. Pharmacoeconomics
James P. Wilson and Karen L. Rascati
Chapter Seven. Evidence-Based Clinical Practice Guidelines
Kevin G. Moores
Chapter Eight. The Application of Statistical Analysis in the Biomedical Sciences
Ryan W. Walters and Karen L. Kier
Chapter Nine. Professional Writing
Patrick M. Malone
Chapter Ten. Legal Aspects of Drug Information Practice
Martha M. Rumore
Chapter Eleven. Ethical Aspects of Drug Information Practice
Linda K. Ohri
Chapter Twelve. Pharmacy and Therapeutics Committee
Patrick M. Malone, Nancy L. Fagan, Mark A. Malesker, and Paul J. Nelson
Chapter Thirteen. Drug Evaluation Monographs
Patrick M. Malone, Nancy L. Fagan, Mark A. Malesker, Paul J. Nelson, and Linda K. Ohri
Chapter Fourteen. Quality Improvement and the Medication Use Process
Mark A. Ninno and Sharon Davis Ninno
Chapter Fifteen. Medication Misadventures I: Adverse Drug Reactions
Philip J. Gregory and Zara Risoldi Cochrane
Chapter Sixteen. Medication Misadventures II: Medication and Patient Safety
Kathryn A. Crea
Chapter Seventeen. Investigational Drugs
Bambi Grilley
Chapter Eighteen. Policy Development, Project Design, and Implementation
Stacie Krick Evans
Chapter Nineteen. Drug Information in Ambulatory Care
Debra L. Parker
Chapter Twenty. Drug Information and Contemporary Community Pharmacy Practice
Morgan L. Sperry and Patricia A. Marken
Chapter Twenty-One. Drug Information Education and Training
Kelly M. Smith
Chapter Twenty-Two. Pharmaceutical Industry and Regulatory Affairs: Opportunities for Drug Information Specialists
Jean E. Cunningham and Lindsay E. Davison
Appendix 2-1. Drug Consultation Request Form
Appendix 2-2. Sample Questions for Obtaining Background Information From Requestors
Appendix 3-1. Performing a PubMed Search
Appendix 3-2. Selected Primary Literatures Sources
Appendix 4-1. Questions for Assessing Clinical Trials
Appendix 5-1. Beyond the Basics: Questions to Consider for Critique of Primary Literature
Appendix 7-1. New Zealand Guidelines Group (NZGG)
Appendix 7-2. National Institute for Clinical Excellence (NICE)
Appendix 7-3. National Institute for Clinical Excellence (NICE) Topic Selection Criteria
Appendix 7-4. Study Selection Process—Centre for Reviews and Dissemination (CRD)
Appendix 7-5. Study Selection Points—Centre for Reviews and Dissemination (CRD)
Appendix 7-6. Data Synthesis—Centre for Reviews and Dissemination (CRD)Appendix 7-7. National Institute for Clinical Excellence (NICE)—Evidence Table Format for Intervention Studies
Appendix 7-8. New Zealand Guidelines Group (NZGG)—Considered Judgment
Appendix 7-9. Guidelines Advisory Committee (GAC) —Levels of Evidence Grades of Recommendation
Appendix 7-10. National Institute for Clinical Excellence (NICE) Guideline Structure
Appendix 7-11. Scottish Intercollegiate Guidelines Network (SIGN) Consultation and Peer-Review
Appendix 7-12. Grades of Recommendation Assessment Development and Evaluation (GRADE) System Advantages
Appendix 7-13. Appraisal of Guidelines Research & Evaluation (AGREE) Instrument
Appendix 7-14. Conference on Guideline Standardization (COGS) Checklist
Appendix 7-15. Implementation Strategies
Appendix 9-1. Question Example
Appendix 9-2. Abstracts
Appendix 9-3. Bibliography
Appendix 11-1. Code of Ethics for Pharmacists
Appendix 12-1. Pharmacy and Therapeutics Committee Procedure
Appendix 12-2. Formulary Request Form
Appendix 12-3. P&T Committee Meeting Attributes
Appendix 12-4. Example P&T Committee Minutes
Appendix 12-5. Chairperson Skills
Appendix 12-6. Conflict-of-Interest Declaration
Appendix 13-1. Format for Drug Monograph
Appendix 13-2. Example Drug Monograph
Appendix 14-1. Comparison of Quality Assurance and Total Quality Management in Health Care
Appendix 14-2. Tools Used in Quality Improvement
Appendix 14-3. Examples of Approaches to Quality Improvement
Appendix 14-4. Example of a Quality Improvement Activity Plan
Appendix 14-5. Example Report—Prescriber-Specific Results
Appendix 14-6. Example of MUE Results
Appendix 14-7. Quality Evaluation: Response to Drug Information Request
Appendix 15-1. Kramer Questionnaire
Appendix 15-2. Naranjo Algorithm
Appendix 15-3. Jones Algorithm
Appendix 15-4. MedWatch Form
Appendix 17-1. Investigational New Drug Application
Appendix 17-2. Statement of Investigator
Appendix 17-3. Protocol Medication Economic Analysis
Appendix 17-4. Investigational Drug Accountability Record
Appendix 18-1. High-Alert Medications
Appendix 18-2. Medication Shortages and Backorders
Appendix 19-1. FDA Guidelines for Proper Medication Disposal
Appendix 22-1. Response Letter: Drug A—Incidence of Yellow Stripes
Glossary
Answers for Case Studies
Answers for Self-Assessment Questions
Index